Luteolin 7-O-glucoside acts as a novel ADC payload with anti-proliferative properties, supporting antibody-drug conjugates in targeted cancer therapy by interfering with tumor cell signaling pathways.
Structure of 5373-11-5
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
100 mg | $299 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Luteolin 7-O-glucoside is a flavonoid glycoside that can function as an ADC cytotoxin in antibody-drug conjugates. Its cytotoxic mechanism involves modulation of cellular signaling pathways, inhibition of proliferation, and induction of apoptosis in tumor cells. The glucoside moiety enhances solubility and enables efficient conjugation to antibodies via cleavable or non-cleavable linker chemistries, allowing targeted delivery of the payload.
In antibody-drug conjugates, Luteolin 7-O-glucoside is covalently attached to monoclonal antibodies using linker strategies designed for systemic stability and controlled intracellular release. The ADC remains inactive in circulation, reducing off-target effects, while enzymatic cleavage within tumor cells releases the active payload. This selective delivery ensures that cytotoxic effects occur specifically in antigen-expressing cells, maintaining precision in tumor-targeted therapy.
Applications of Luteolin 7-O-glucoside include its incorporation into ADCs targeting solid tumors and hematologic malignancies. Its chemical structure is compatible with a variety of linker systems, allowing optimization of conjugation efficiency, intracellular release kinetics, and pharmacokinetic properties. The compound exhibits reproducible cytotoxic activity in target-expressing cell lines and supports the design of ADCs with defined mechanisms of action and controlled antitumor effects.
What is Luteolin 7-O-glucoside?
Luteolin 7-O-glucoside is a flavonoid glycoside with potential cytotoxic activity, often studied as a payload in ADC development. It can modulate cellular signaling and apoptosis pathways, making it suitable for selective delivery to target cells via antibody conjugation.
5/4/2018
Dear team, how does Luteolin 7-O-glucoside function in ADCs?
When used as an ADC payload, Luteolin 7-O-glucoside exerts its effects by interfering with key signaling and apoptotic mechanisms in targeted cancer cells. Conjugation to antibodies ensures selective delivery, reducing systemic toxicity and enhancing therapeutic index.
21/11/2020
Dear team, which linkers are compatible with Luteolin 7-O-glucoside?
Luteolin 7-O-glucoside can be conjugated using cleavable linkers such as peptide-based or chemically sensitive linkers. Proper linker selection enables controlled intracellular release and maintains stability of the ADC in systemic circulation.
9/3/2019
Could you please let me know if Luteolin 7-O-glucoside can be used in preclinical ADC studies?
Yes, Luteolin 7-O-glucoside is commonly used in preclinical ADC research to evaluate cytotoxicity, efficacy, and pharmacokinetics. These studies help optimize payload delivery and ADC design for potential clinical applications.
7/1/2021
Good afternoon! What safety precautions are recommended when handling Luteolin 7-O-glucoside?
Handling Luteolin 7-O-glucoside requires strict laboratory safety protocols, including personal protective equipment, containment measures, and proper waste management to prevent exposure to its cytotoxic effects during conjugation and research.
5/12/2016
— Dr. Peter Hall, Senior Scientist (USA)
Luteolin 7-O-glucoside delivered by BOC Sciences showed excellent purity and stability.
9/3/2019
— Dr. Thomas White, Research Director (USA)
Luteolin 7-O-glucoside was delivered with outstanding quality, helping us evaluate its role in novel linker systems.
5/12/2016
— Ms. Anna Müller, Senior Scientist (Germany)
The team at BOC Sciences provided detailed analytical data for Luteolin 7-O-glucoside, which gave us confidence in the results.
7/1/2021
— Dr. Patrick Lewis, Laboratory Head (UK)
We tested Luteolin 7-O-glucoside in conjugation studies, and its performance was consistent across multiple trials.
5/4/2018
— Mr. George Lambert, ADC Development Manager (France)
Excellent communication and timely delivery of Luteolin 7-O-glucoside made our experience with BOC Sciences outstanding.
— Dr. Sofia Andersson, Biotech Scientist (Sweden)
The batch-to-batch reproducibility of Luteolin 7-O-glucoside is remarkable. This reliability is critical for our ongoing ADC work.
21/11/2020
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.